Skip to content
Peptide Evidence Registry

GLP-1s & incretins · Metabolic & endocrine

MBX 6180

A preclinical triple GLP-1, GIP and glucagon receptor agonist prodrug nominated as a development candidate in August 2026.

L1Theory onlyResearch / unapproved supplyPreclinical
How settled this rating is:
very-low confidence in the current evidence rating
Routes studied:
Subcutaneous injection
Also known as:
GLP-1/GIP/glucagon triple-agonist prodrug
Last reviewed:
2026-09-20
Jump to section

Evidence passport

MBX 6180

A one-screen evidence identity for this compound. These fields describe research maturity, confidence and legal status. They are not a safety guarantee, efficacy percentage or recommendation.

Reviewed 2026-09-20
Evidence level
L1Theory only
Confidence
Very low confidence in rating
Regulatory status
Research / unapproved supply
Development status
Preclinical

Evidence strength

Human efficacy evidence0 of 100 evidence strength

Higher = more and better-quality human evidence. It does not mean the effect is bigger or that the compound works for you.

Human safety evidence0 of 100 evidence strength

Higher = more mature, better-documented human safety data. It does not mean the compound is safer than one with a lower number.

The 0-100 values rate the strength and maturity of evidence, not how effective or safe the compound is.

Evidence base
Mostly animal and laboratory research
Furthest established stage
Preclinical
Human research maturity
Preclinical / IND-enabling; development candidate nominated August 2026
Source curation
Sources fully curated

Routes recorded

SC injection

Most of this evidence comes from animals and cells

The supporting research for MBX 6180 is predominantly preclinical (Level 1–2). That is a legitimate starting point for science and a poor basis for personal decisions. Human results are not simply a scaled-up version of mouse results.

Overview

Human efficacy evidence strength0 of 100 evidence strength

Higher = more and better-quality human evidence. It does not mean the effect is bigger or that the compound works for you.

Preclinical (animal / lab) evidence strength28 of 100 evidence strength

Higher = more animal, tissue or cell research. Preclinical results are a starting point, not proof of a human benefit.

Human safety evidence strength0 of 100 evidence strength

Higher = more mature, better-documented human safety data. It does not mean the compound is safer than one with a lower number.

How to read these scores

Every number here rates the evidence, not the compound. They are editorial 0-100 strength ratings, not percentages, and not a rating out of five stars.

  • Human efficacy evidence strength — Higher = more and better-quality human evidence. It does not mean the effect is bigger or that the compound works for you.
  • Preclinical evidence strength — Higher = more animal, tissue or cell research. Preclinical results are a starting point, not proof of a human benefit.
  • Human safety evidence strength — Higher = more mature, better-documented human safety data. It does not mean the compound is safer than one with a lower number. A score of 80 does not mean “80% safe”.
  • Evidence level (L0-L5) — the strongest type of study behind the compound, from anecdote (L0) to large replicated human trials (L5). It is a description of the study evidence, not a quality, safety or recommendation rating.
  • Confidence — how likely we think it is that this rating changes as new research lands. Low confidence means the picture is unsettled, not that the compound is bad.

None of these ratings is medical advice, a safety guarantee, or a recommendation to use anything. How we grade evidence.

How far human research has progressed: Preclinical / IND-enabling; development candidate nominated August 2026

Routes & formulations

Studied / approved routes

SC injection

Route availability is not evidence of efficacy, and evidence from one route does not transfer to another. The Registry never provides dosing or sourcing information.

Peptide lifecycle

  1. Discovery

  2. Preclinical

    Furthest established stage

  3. Phase I

  4. Phase II

  5. Phase III

  6. Approved

Preclinical

Last documented development: August 2026 — development candidate nomination

What it is

A prodrug of a single triple agonist peptide targeting the GLP-1, GIP and glucagon receptors — the same receptor set as retatrutide, delivered through a slow-release prodrug design.

What people claim

  • Retatrutide-like results with longer dosing intervals

What the evidence actually says

What people claim: that a long-acting triple agonist will match or beat retatrutide with fewer injections. What the evidence actually says: this molecule was nominated as a development candidate in August 2026 and has no human data. Sharing receptor targets with a Phase 3 molecule is not shared evidence.

Related evidence

Useful next reads based on this compound — not recommendations.

Human evidence

  • None. No human study is established in our curated record.

Preclinical evidence

  • Sponsor disclosure describes a GLP-1/GIP/glucagon triple-agonist prodrug nominated as a development candidate in August 2026.

Animal and cell findings are Level 1–2 evidence.

Mechanism and pathways

Triple agonistOne molecule acting at three named receptors.

Receptor targets: GLP-1 receptor, GIP receptor, Glucagon receptor

Mechanism class counts the receptors the pharmacology engages and says whether one molecule or several drugs do it. More targets is not the same as more effective, and none of these labels is a receptor name — there is no GLP-3, GLP-4 or GLP-5 receptor.

  • The three-receptor combination is the same as retatrutide's; the prodrug element is about duration rather than a new mechanism.
  • Glucagon receptor agonism is included for energy expenditure, and also requires careful glucose monitoring in human trials.

Safety and unknowns

  • No human safety data.

Cancer relevance

This section covers questions raised by how the compound works in the body, plus anything regulators and trial teams keep an eye on. It is not a statement that this compound causes cancer — for most compounds here, no human data exist in either direction.

No established human signal

Not established. No human data exist.

Regulatory status

Regulatory decisions apply to specific jurisdictions, products, formulations and indications. An approval elsewhere is not automatically an approval in your country.

Check the regulatory note and linked primary sources for jurisdiction-specific details.

Preclinical / IND-enabling. Candidate nomination is an internal development decision, not a regulatory step and not evidence of benefit.

Evidence grade

L1Theory onlyVery low confidence in rating

Mechanistic rationale or early development without qualifying compound-specific outcome evidence. A registered trial is not a result.

What would change our rating?

  • IND clearance and a registered first-in-human trial.
  • Published preclinical data.

References and sources

Source transparency

A provenance snapshot of this profile. Counts show what kinds of sources are cited, not how much scientific weight each source deserves.

Sources fully curated
Last editorial review
2026-09-20
Recently reviewed · 26 days ago
Linked curated sources
2
Sources still pending
0
External specialist reviews
0
None recorded for this profile
Sponsor / official: 2

Review provenance

Registry editorial review: Colin Jackson-White, creator and editor, who is not a doctor or clinician. External specialist review is credited only when a named reviewer has completed a review of this exact profile.

Current linked evidence is sponsor-only. Treat findings as provisional until independent or peer-reviewed documentation is available.

Literature-discovery and AI tools may help locate or challenge candidate evidence, but they are not counted as evidence sources here. Registry judgements are tied to the underlying papers, trial records, regulator documents and official study records.

Source hierarchy: regulatory documents and trial registries first, peer-reviewed work next, sponsor material flagged as non-independent. We never use supplier or clinic marketing as evidence, and where a verified source has not yet been curated we say so rather than inventing one.

Evidence change history

These entries record changes to our assessment of the published evidence — not changes to the compound itself.

No recorded changes yet. Baseline position set on 2026-09-20.